
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Biocon | stock market trading

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Integrated Core Strategies (Asia) Pte on Tuesday bought shares of biopharmaceutical company Biocon for Rs 185 crore through an open market transaction.
According to the bulk deal data available with the National Stock Exchange (NSE), Integrated Core Strategies (Asia) Pte purchased 80,61,599 shares at an average price of Rs 229.26 each share. The aggregate deal value is Rs 184.82 crore.
Details about the sellers could not be immediately ascertained.
On Tuesday, shares of Biocon closed marginally lower at Rs 229.50 apiece on NSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Tue, February 28 2023. 22:06 IST
The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more
The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more
Monzo is preparing a renewed push to secure a US banking licence, four years after abandoning its first attempt when tal... Read more
America’s cryptocurrency companies are scrambling to secure a foothold in the country’s traditional banking system, ... Read more
Parallel Banking: How Stablecoins Are Building a New Global Payments SystemStablecoins—digital currencies pegged to tr... Read more
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more